The p2B3- and bmDb8 were labeled with124I and evaluated for tumor targeting and microPET imaging of prostate cancer xenografts in order to assess the impact of affinity onin vivodelivery

The p2B3- and bmDb8 were labeled with124I and evaluated for tumor targeting and microPET imaging of prostate cancer xenografts in order to assess the impact of affinity onin vivodelivery. == Materials and methods == == Diabody gene assembly and affinity maturation strategy == An scFv fragment in the VLVHorientation with an 18 amino acid linker and a six histidine tag was amplified from a plasmid encoding the 2B3 minibody (Leytonet al., 2008). were determined by surface plasmon resonance. Back-mutation restored the affinity from 5.4 to 1 1.9 nM. Stability, evaluated by size exclusion, revealed that diabodies with eight-residue linkers existed as a Amikacin disulfate mixture of dimeric and monomeric species at low concentrations (1 mg/ml). Shortening the linker from eight to five residues improved dimer stability, notably in the bm2B3-Db8 compared with bm2B3-Db5. Both p2B3-Db8 and bm2B3-Db8 were radioiodinated with124I and evaluated by serial micro-positron emission tomography imaging in mice bearing LAPC-9 human prostate cancer xenografts. Localization in LAPC-9 xenografts was seen at 4 h, whereas at 20 h most of the activity had cleared from the tumor. Highest tumor-to-background contrast ratios and best images were obtained at 12 h. Although the higher affinity bm2B3-Db8 demonstrated improved tumor retention at later time points (20 h), it did not improve tumor targeting or imaging compared with p2B3-Db8 at 12 h. Keywords:affinity maturation, diabody, PET, prostate cancer, PSCA == Introduction == The humanized 2B3 monoclonal antibody (hu2B3 mAb) can localize to and image the GPI-linked prostate stem cell antigen (PSCA) in xenograft-bearing mice (Olafsenet al., 2007). PSCA has been shown to be a promising target for antibody-based imaging and therapy of prostate cancer (Saffranet al., 2001;Olafsenet al., 2007) due to its abundant expression in the majority of primary and androgen-independent prostate cancers specimens and its correlation with higher disease stage (Guet al., 2000;Lamet al., 2005). An analysis of circulating tumor cells by RTPCR suggested that PSCA was more promising as a molecular diagnostic than prostate-specific antigen (PSA) or prostate-specific membrane antigen (PSMA) in men with prostate cancer (Haraet al., 2002). Additionally, PSCA expression has been associated with a subset of prostate epithelial cells that were shown to represent a cancer-specific transitional population (Tranet al., 2002). A major goal for prostate cancer imaging is to achieve more accurate disease detection and characterization (Hricaket al., 2007). The mainstays for detection and staging of prostate cancer continue to be ultrasound, CT, MRI and MRS, although nuclear medicine approaches are expanding. Much work has been with metabolic-specific probe development, with [11C]-choline, [18F]-choline and [11C]-acetate appearing especially promising Amikacin disulfate as tracers sensitive to the increased fatty acid metabolism exhibited by these malignancies (reviewed inBouchelouche and Oehr, 2008a,2008b). The development and approval of [111In]-capromab pendetide (ProstaScint) displayed one of the first examples of an antibody imaging agent focusing on a tissue-specific marker in tumors, namely PSMA. Prostate-associated antigens, such as PSCA, PSMA and Mindin/RG-1, have been targeted using radioiodinated antibodies for Amikacin disulfate tumor imaging in preclinical studies (Smith-Joneset al., 2003;Parryet al., 2005;Olafsenet al., 2007). Despite the ability of antibodies to efficiently deliver high tumor radioactive uptake, their prolonged blood residence results in high background transmission making early imaging of malignancy lesions hard. The antibodies focusing on PSMA, Mindin/RG-1 and PSCA have all required days (27 days) for the blood to clear plenty of in order to obtain high contrast tumor images. For PSMA, improvements that produced good tumor-to-blood ratios at early time points were achieved by enzymatically reducing the molecular excess weight of PSMA-targeting antibodies (Carteret al., 2004). Radioiodinated Fab and F(ab)2fragments displayed ideal focusing on instances at 24 and 48 h, BCL2L8 respectively. Diabodies (Dbs; 55 kDa) are bivalent antibody fragments composed of two non-covalently certain scFv fragments. Their bivalency offers been shown to enhance tumor retention compared with monovalent fragments of equivalent molecular excess weight (Adamset al., 2006). Diabodies are manufactured into dimeric varieties through manipulation of the linker peptide linking the variable (V) domains in either the VLVHor the VHVLorientation. Generally, the use of linker from 3 to 12 amino acids has been shown to promote the association to a diabody (Holligeret al., 1993;Perisicet al., 1994;Wuet al., 1996;Dolezalet al., 2000). Reducing the linker size further results in different patterns of oligomerization (Dolezalet al., 2000). However, linker length rules are not rigid, and the transitions between dimer, trimer and tetramer forms can be highly dependent on the individual antibody under study. For example, scFvs constructed from a CD22-specific antibody by Amikacin disulfate direct Amikacin disulfate fusion into VL-0-VHconstructs resulted in an almost pure dimer human population (Arndtet al., 2004), yet the affinity of the anti-CD22 dimer was much like its monovalent scFv counterpart, suggesting that only.